CAR-engineered immune cells and Treg-cell therapies show biological plausibility but limited human evidence in IBDImmune Cell Therapies Show Potential for Inflammatory Bowel Disease

Frontiers in Medicine Published September 3, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that CAR-engineered and Treg-cell therapies for IBD are promising but remain in early investigational stages.

This systematic review evaluates the rationale and current evidence for CAR-engineered immune cells and regulatory T (Treg)-cell-based therapies in the management of inflammatory bowel disease (IBD). The review synthesized data from 11 studies to assess biological plausibility, feasibility, and clinical evidence.

Findings indicate that while preclinical studies and early translational data support the biological plausibility and feasibility of these cellular immunotherapies, human evidence remains limited. The current clinical landscape is characterized by sparse experience and short follow-up durations. Key challenges identified for clinical translation include concerns regarding cellular persistence, phenotypic stability, antigen selection, manufacturing scalability, and long-term safety.

Clinically, these therapies represent a promising but investigational paradigm for IBD. However, the authors note that robust clinical trials with standardized endpoints and long-term safety monitoring are necessary before these treatments can be adopted into standard clinical practice. The current evidence is insufficient to support immediate clinical application.

How this fits prior evidence

This systematic review addresses a gap in the current management of inflammatory bowel disease by evaluating novel cellular immunotherapies. While prior coverage has identified specific microbial shifts following infliximab treatment and the potential for GLP-1RAs to reduce systemic inflammation in IBD, this review focuses on the investigational status of CAR-engineered cells and Treg-cell-based therapies. It confirms that while these therapies are biologically plausible, they currently lack the robust clinical trial data required for standard practice.

Researchers reviewed the use of CAR-engineered immune cells and regulatory T (Treg) cells to treat inflammatory bowel disease. These types of therapies aim to modify the immune system to manage the condition. The review looked at the logic behind these treatments and the data available so far.

While early data from laboratory studies and initial translations suggest these therapies are scientifically plausible, human evidence is still very limited. Most of the current clinical experience is sparse, and the follow-up periods for patients have been short. This means we do not yet have a full picture of how these treatments work over a long period of time.

Because these treatments are still in the investigational stage, they are not yet standard care. There are several hurdles to overcome, such as ensuring the cells stay stable and can be manufactured on a large scale. More large clinical trials are needed to confirm safety and effectiveness before these therapies can be widely used.

What this means for you:

Immune cell therapies show promise for inflammatory bowel disease but require more large-scale human trials.

Common questions

What are CAR-T and Treg-cell therapies?

These are types of cellular immunotherapies. CAR-engineered immune cells and regulatory T (Treg) cells are being studied to see if they can treat inflammatory bowel disease. They work by targeting the immune system to manage the condition.

Is this treatment currently available for everyone?

No, these therapies are still considered an investigational paradigm. Because human evidence is limited and clinical experience is sparse, more robust clinical trials are needed before these treatments can be adopted into standard medical practice.

What are the main challenges for these therapies?

Several factors need more study before these treatments are widely used. These include cellular persistence, phenotypic stability, antigen selection, and manufacturing scalability. Long-term safety monitoring is also required to ensure the treatments are safe for patients.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

View Original Abstract ↓

BackgroundInflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by dysregulated mucosal immunity. Despite major advances in therapies, a high proportion of patients do not achieve or sustain remission. Cellular immunotherapies have emerged as a mechanistically distinct therapeutic strategy with potential relevance for refractory disease. In the present paper, the authors aim to evaluate the rationale and current evidence supporting chimeric antigen receptor (CAR)-engineered immune cells and regulatory T (Treg)-cell–based therapies in IBD. Preclinical studies and early translational data support biological plausibility and feasibility of these therapies. However, available human evidence remains limited, with sparse clinical experience and short follow-up.MethodsA systematic review was conducted according to PRISMA guidelines. Search was performed in PubMed and EMBASE databases from inception to February 2026 including terms like “IBD”, “CAR-T”, “CAR-Treg” and “Treg therapy” among others. Eligible studies included preclinical, translational and clinical reports evaluating CAR-engineered immune cells in IBD models.ResultsA total of 11 studies met the inclusion criteria after the screening and were included in the review. CAR-Treg technologies build upon advances achieved with conventional CAR-T cells in oncology and enable antigen-specific immune regulation rather than cytotoxicity. Preclinical studies and early translational data support biological plausibility and feasibility. However, available human evidence remains limited, with sparse clinical experience and short follow-up. Major unresolved issues include cellular persistence, phenotypic stability (particularly for Tregs), optimal antigen selection, manufacturing scalability, and long-term safety.ConclusionsCellular immunotherapies represent a promising but still investigational therapeutic paradigm in IBD. Robust clinical trials with standardized endpoints and long-term safety monitoring are needed before their clinical adoption.

CAR-engineered immune cells and Treg-cell therapies show biological plausibility but limited human evidence in IBDImmune Cell Therapies Show Potential for Inflammatory Bowel Disease

How this fits prior evidence

Common questions

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

CAR-engineered immune cells and Treg-cell therapies show biological plausibility but limited human evidence in IBDImmune Cell Therapies Show Potential for Inflammatory Bowel Disease

How this fits prior evidence

Common questions

More on Inflammatory Bowel Disease

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties